纤维化药物有效性评估基于微流体机械性质评估的球状模型的纤维化药物有效性评估
Bolam Kim1, Jeong Yeon Kim1, Hye Won Kim1
1Department of Chemical and Biological Engineering, Korea University, Seoul, 02841, Republic of Korea.
Advanced healthcare materials
|March 17, 2025
概括
一个新的系统测量了球形力学,以了解肺纤维化等纤维性疾病. 它揭示了细胞相互作用和治疗如何影响组织硬性,有助于抗纤维性治疗的发展.
科学领域:
- 生物医学工程 生物医学工程
- 细胞生物学 细胞生物学
- 生物物理学的生物物理.
背景情况:
- 纤维性疾病,包括肺纤维化,存在重大研究和治疗障碍.
- 现有的机械评估系统在研究复杂的纤维化过程方面存在局限性.
研究的目的:
- 开发和验证一种基于碰撞的新型球形机械性能评估系统.
- 在肺纤维化模型中分析细胞变形性,并评估治疗干预措施.
主要方法:
- 利用惯性流体动力学来控制球体碰撞和用于应变测量的高速摄像头.
- 用HEK293T球体验证了系统,分析了Calu-1和MRC-5细胞的变形性.
- 开发了共同培养球状体模型,并用转化生长因子-β1 (TGF-β1) 和Nintedanib处理了球状体.
主要成果:
- 在共同培养模型中,根据细胞组成观察到球形变形能力的显著差异.
- 证明球形力学反映了细胞-细胞和细胞-细胞外矩阵 (ECM) 相互作用.
- 在用TGF-β1和抗纤维药物Nintedanib治疗后,机械性质出现了变化.
结论:
- 开发的系统有效地反映了与纤维化疾病进展相关的机械特性.
- 这个平台提供了对纤维化病的更深入的了解,并加速了抗纤维化药物开发.
相关概念视频
In Vitro Drug Dissolution: Compendial Testing Models I
Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
In Vitro Drug Dissolution: Compendial Testing Models II
Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients, maintaining...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


